Tuesday, November 29, 2022
Home Tags Pharma

Pharma Related News

Lisdexamfetamine is the safest medication for people with drug addiction

Lisdexamfetamine is the safest medication for people with drug addiction

Lisdexamfetamine, a medication for ADHD, has the lowest risk of hospitalisation and death in people with amphetamine addiction, according to research from Karolinska Institutet...
New high blood pressure treatment works on resistant patients

New high blood pressure treatment works on resistant patients

A new drug has been shown to significantly reduce hypertension in patients who do not respond to existing high blood pressure treatment. According to results...
Making pharma supply chains more sustainable

Making pharma supply chains more sustainable

Nico Ros, Co-Founder and CTO of SkyCell discusses how to make pharma supply chains more sustainable. As businesses everywhere look for ways to reduce their...
Enhancing the efficacy of cancer vaccines and antibody drug conjugates

Enhancing the efficacy of cancer vaccines and antibody drug conjugates

In its quest to optimise treatment for cancer and infectious diseases, Defence Therapeutics illustrates how its groundbreaking Accum technology elevates the performance of vaccines...
Study examines the effectiveness of remdesivir in a pill form for COVID-19

Study examines the effectiveness of remdesivir in a pill form for COVID-19

Scientists at the University of North Carolina at Chapel Hill are testing remdesivir in a pill form to understand how effective it is for...

Defence Therapeutics: Optimising drug efficacy with AccumTM technology

Health Europa is excited to introduce the latest captivating eBook from industry pioneers of the biotechnology sector, Defence Therapeutics, who comprehensively elucidate their revolutionary...
neurodegenerative-diseases

A new hope for treating neurodegenerative diseases

NervGen’s NVG-291 is a new drug with the potential to treat a range of neurodegenerative diseases, including Alzheimer's and MS. IT is the Holy Grail...
Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells

Trial begins for world-first multivariant COVID-19 vaccine booster

A phase one trial for the world’s first multivariant COVID-19 booster vaccine has been launched in Manchester. Initiated by pharmaceutical company Gritstone, in partnership with...
HPV vaccine

Defence Therapeutics unveil novel HPV vaccine development programme

Industry-leading biotechnology company Defence Therapeutics has revealed that it will be establishing a high priority programme to develop a new HPV vaccine for cervical...
cancer-vaccine

Cancer vaccine developed using Oxford-AstraZeneca vaccine technology

Scientists are utilising the same technology used in the creation of the Oxford-AstraZeneca COVID-19 jab to develop a vaccine to treat cancer. Researchers at the...
opioid-overdose

Researchers issue opioid warning as they reveal overdose findings

Hundreds of patients could have died from an accidental overdose of prescription opioids, the findings from a recent study have revealed. Research led by Dr...
heart-failure-patients-AI

AI identifies heart failure patients best suited to beta-blocker treatment

A new AI-based approach could help to quickly and easily identify the best treatment options for heart failure patients. Researchers from the University of Birmingham...
drug-delivery-Defence-Therapeutics

Defence Therapeutics selects new variants to optimise drug delivery

Following a thorough evaluation process, Defence Therapeutics has selected the eight most successful variants of its Accum™ drug delivery technology. Biotechnology company Defence Therapeutics continually works...
heart-failure

Lung disease drug offers hope for heart failure patients

A drug currently used to treat lung fibrosis could be repurposed to treat heart failure patients, an early phase trial has suggested. Doctors and scientists...
intranasal-vaccine

Pre-clinical trials show intranasal COVID-19 vaccine reduces infection risk

Researchers have made a significant breakthrough in the development of an intranasal COVID-19 vaccine. Scientists from Lancaster University have carried out pre-clinical trials of a...
SARS-CoV-2-infection

Cholesterol drug could reduce SARS-CoV-2 infection by up to 70%

Scientists have identified a licensed drug that they say could significantly reduce the risk of COVID-19 infection. An international study, led by the University of...
Defence-Therapeutics

Defence Therapeutics partners with pharmaceutical experts

Biotechnology company Defence Therapeutics has partnered with a pharmaceutical consultancy to maximise the potential of its developments. In a bid to strengthen its development of...

NervGen: Repairing the Nervous System

Backed by over three decades of thorough research, NervGen’s drug candidate has the potential to repair damage to the nervous system. Canadian R&D innovator NervGen...
COVID-19-blood-clots

Existing drugs could prevent blood clots in severe COVID-19 cases

New findings that COVID-19-related blood clots may be caused by an abnormal antibody response could help to identify preventative treatments. Researchers have demonstrated how antibodies...
Pfizer-vaccine

Longer interval between Pfizer vaccine doses boosts antibody protection

A longer dosing schedule for the Pfizer COVID-19 vaccine triggered the most effective immune response, new research has found. A new and extensive pre-print study...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest